Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
For patients, we provide the latest patient information leaflets and training materials as well as the technical information for Berlin-Chemie products available in Germany via our Medical Hub.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
Discover More about Global Responsibility
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Discover More about Global Partnering
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Menarini Blog
Follow Us
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Our Job Portal
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
2022 - 01 - 17
Menarini Diagnostics CoronaMeltVAR Real-Time PCR kit simultaneously detects SARS CoV-2 and identifies the Omicron Variant
The new Omicron variant is spreading rapidly causing an increase in infections at unprecedented speed. On November 28th, WHO officially recommended laboratories to use Real Time PCR detection kits capable of identifying putative Omicron variant infections, directly at the moment of the positivity test.
To support this recommendation, Menarini offers CoronaMeltVAR, a CE-IVD Real-Time PCR kit based on intercalating dye and melting curve analysis. The kit detects positive samples with high sensitivity, through the amplification of two targets, both compatible with all variants and with the wild type form, simultaneously revealing with distinct signals the suspect presence of Omicron Variant BA.1, BA.2, as well as Alpha, Beta/Gamma and WT/Delta.
All responses are obtained in a single run on each sample, with no loss of sensitivity compared to normal kits and without the need to perform a second reflex test on positive samples. The kit is compatible with most RNA extraction protocols and Real-Time PCR instruments capable of performing melting curve analysis at moderate resolution. CoronaMeltVAR provides SARS CoV-2 CE IVD detection and Omicron surveillance in less than 2 hours.
"We are extremely proud to have made this unique solution available so quickly. It is helping healthcare professionals in providing a specific, rapid and accurate solution for the diagnosis and identification of Covid-19 Omicron variant", said Fabio Piazzalunga, General Manager & Global Head of A.Menarini Diagnostics and Chairman/CEO of Menarini Silicon Biosystems.
A.Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world.
A.Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today it is present in 140 countries throughout the world, it counts more than 17,000 employees and has a 2020 turnover of € 3.750 billion.
www.menarinidiagnostics.com
Menarini Group Contacts:
Valeria Speroni Cardi
Email: pressoffice@menarini.com